SmartPharm
Gene therapy company applying the next generation of non-viral DNA and RNA technologies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Related Content
SmartPharm Therapeutics is a pioneering company in the field of gene therapy, focusing on non-viral gene encoded therapeutics (GET) to address serious and rare diseases, including COVID-19. The company operates in the biotechnology sector and serves clients such as government agencies, healthcare providers, and pharmaceutical companies. SmartPharm's business model revolves around developing DNA-based neutralizing antibodies that can be administered via intramuscular injection to block infections. This approach offers multiple benefits over traditional viral vectored gene therapy, including minimal immunogenicity, re-dosability, and reduced regulatory complexity. The company generates revenue through government contracts, such as the one awarded by the Defense Advanced Research Projects Agency (DARPA), and partnerships with pharmaceutical firms. SmartPharm leverages its advanced technological capabilities and integrated engineering insights to produce optimal gene encoded therapeutics, aiming to improve therapy effectiveness, enhance patient quality of life, and extend the global reach of biologics therapy.
Keywords: gene therapy, non-viral, COVID-19, DNA-based, neutralizing antibodies, biotechnology, DARPA, scalable manufacturing, rare diseases, healthcare.